RecruitingNCT05847855
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
Studying Neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fudan University
- Principal Investigator
- Xianjun Yu, MD, PhDFudan University
- Intervention
- Blood collection(diagnostic_test)
- Enrollment
- 1000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (2)
- Fudan University shanghai cancer center, Shanghai, Shanghai Municipality, China
- West China Hospital, Sichuan University, Chengdu, Sichuan, China
Collaborators
West China Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05847855 on ClinicalTrials.govOther trials for Neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07273409Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or NotUppsala University
- ENROLLING BY INVITATIONPHASE2NCT07121478Patients With High-grade Pancreatic Neuroendocrine TumorsNational Cancer Center, Korea
- RECRUITINGPHASE2, PHASE3NCT06943755Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsExelixis
- RECRUITINGPHASE1NCT06663072Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsUniversity of Chicago
- RECRUITINGPHASE1NCT05687123Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06406387ATRX/DAXX in EUS-FNB Specimens of Pan-NETsAzienda Ospedaliera Universitaria Integrata Verona
- RECRUITINGNCT06121622Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine TumoursIRCCS San Raffaele
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06148636A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsDavid Bushnell